Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Accounts Payables (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Accounts Payables readings, the most recent being $4.6 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 43.01% to $4.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.6 million, a 43.01% increase, with the full-year FY2025 number at $4.6 million, up 43.01% from a year prior.
  • Accounts Payables hit $4.6 million in Q4 2025 for Fennec Pharmaceuticals, down from $5.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.9 million in Q2 2025 to a low of $677000.0 in Q2 2021.
  • Median Accounts Payables over the past 5 years was $3.0 million (2023), compared with a mean of $3.2 million.
  • Biggest five-year swings in Accounts Payables: crashed 75.43% in 2021 and later skyrocketed 207.59% in 2022.
  • Fennec Pharmaceuticals' Accounts Payables stood at $777000.0 in 2021, then skyrocketed by 207.59% to $2.4 million in 2022, then skyrocketed by 58.08% to $3.8 million in 2023, then dropped by 14.21% to $3.2 million in 2024, then soared by 43.01% to $4.6 million in 2025.
  • The last three reported values for Accounts Payables were $4.6 million (Q4 2025), $5.9 million (Q3 2025), and $5.9 million (Q2 2025) per Business Quant data.